All In Biotech

Drug Trial Radar · NCT02763319

A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

A Phase 2/3, Randomised, Multicentre Study of Tafasitamab With Bendamustine Versus Rituximab With Bendamustine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT)

Last checked: Nov 20, 2026Latest source record: Jul 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 453 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

453

Actual

Start

Nov 28, 2016

Primary completion

Jun 21, 2024

Study completion Jun 21, 2024

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
First posted
May 5, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare the safety and efficacy of Tafasitamab with BEN versus RTX with BEN in adult patients with relapsed of refractory DLBCL.

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

  • Rituximab (RTX)Drug

    Rituximab: Dose: 375 mg/m2 IV

  • TafasitamabDrug

    Tafasitamab: Tafasitamab dose: 12 mg/kg intravenously (IV)

  • Bendamustine (BEN)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Overall PopulationTime frame: up to 41.4 months
  2. Kaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Natural Killer Cell Count-Low SubgroupTime frame: up to 46.5 months

Locations

158 sites in 23 countries. Site status is shown where the registry gives one.

  • MorphoSys Research Site

    Anaheim, California

  • MorphoSys Research Site

    Bakersfield, California

  • Morphosys Research Site

    Burbank, California

  • Morphosys Research Site

    Fresno, California

  • MorphoSys Research Site

    Los Angeles, California

  • MorphoSys Research Site

    Whittier, California

  • MorphoSys Research Site

    Plainville, Connecticut

  • MorphoSys Research Site

    Skokie, Illinois

  • MorphoSys Research Site

    Detroit, Michigan

  • MorphoSys Research Site

    Rochester, Minnesota

  • MorphoSys Research Site

    Hattiesburg, Mississippi

  • Morphosys Research site

    Jackson, Mississippi

  • Morphosys Research Site

    Morristown, New Jersey

  • MorphoSys Research Site

    New York, New York

  • MorphoSys Research Site

    Stony Brook, New York

  • MorphoSys Research Site

    Oklahoma City, Oklahoma

  • MorphoSys Research Site

    Knoxville, Tennessee

  • Morphosys Research Site

    Lubbock, Texas

  • MorphoSys Research Site

    Adelaide, Australia

  • MorphoSys Research Site

    Albury, Australia

  • MorphoSys Research Site

    Bedford Park, Australia

  • MorphoSys Research Site

    Box Hill, Australia

  • MorphoSys Research Site

    Concord, Australia

  • MorphoSys Research Site

    Frankston, Australia

  • MorphoSys Research SIte

    Garran, Australia

  • MorphoSys Research Site

    Geelong, Australia

  • MorphoSys Research Site

    Gosford, Australia

  • MorphoSys Research Site

    Nedlands, Australia

  • MorphoSys Research Site

    South Brisbane, Australia

  • MorphoSys Research Site

    St Albans, Australia

  • MorphoSys Research Site

    Innsbruck, Austria

  • MorphoSys Research Site

    Saskatoon, Canada

  • Morphosys Research Site

    Edmonton, Alberta, Canada

  • MorphoSys Research Site

    Winnipeg, Manitoba, Canada

  • MorphoSys Research Site

    Saint John, New Brunswick, Canada

  • Morphosys Research Site

    St. John's, Newfoundland and Labrador, Canada

  • MorphoSys Research Site

    Kingston, Ontario, Canada

  • MorphoSys Research Site

    Greenfield Park, Quebec, Canada

  • Morphosys Research Site

    Montreal, Quebec, Canada

  • MorphoSys Research Site

    Zagreb, Croatia

Showing 40 of 158 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.